CSF1R and inflammatory bowel disease: Humans with hypomorphic mutations that dampen CSF-1R signaling might be protected from IBD and, as has been suggested by others [31], therapies inhibiting CSF-1 or CSF-1R may be beneficial in the treatment of this disease.